Bharat Biotech in collaboration with the Indian Council for Agricultural Research(ICAR) has developed the world’s first Biolumpivaxin vaccine for the Lumpy Skin Disease (LSD).

• The vaccine is developed by Biovet which is a Bharat Biotech group firm. 
• The vaccine has recently received approval from the Central Drug Standards Control Organization (CDSCO), marking a significant milestone in India’s veterinary healthcare sector.

Key Features of Biolumpivaxin

• Global First: Biolumpivaxin is the world’s first DIVA (Differentiating Infected from Vaccinated Animals) marker vaccine for Lumpy Skin Disease.
• DIVA Technology: Enables differentiation between naturally infected and vaccinated animals, aiding in disease surveillance and control programs.
• High Safety and Efficacy: The vaccine has been rigorously tested for quality, safety, and effectiveness.
• Single-Dose Regimen: Administered once a year to cattle and buffaloes above 3 months of age.
• Vaccine Strain: Developed using the LSD virus/Ranchi/2019 strain from ICAR-NRCE, Hisar.

Check Out UPSC Modules From PW Store

Lumpy Skin Disease (LSD)

• Lumpy Skin Disease (LSD) is a highly contagious viral disease affecting cattle and buffaloes.
• It is caused by the Lumpy Skin Disease Virus (LSDV), a member of the Poxviridae family. 
• The first reported outbreak of LSD occurred in Zambia in 1929.
• The LSD spreads through blood-sucking vectors like ticks and mites like houseflies, mosquitoes, etc. It also spreads through contaminated water, fodder and feed.
• The disease leads to severe economic losses in the dairy and livestock industry due to reduced milk production, infertility, and mortality.

Ready to boost your UPSC 2025 preparation? Join PW’s UPSC online courses today!